ZCY Stock Chart & Stats
€3.42
-€0.04(-1.39%)
At close: 4:00 PM EDT
€3.42
-€0.04(-1.39%)
Day’s Range― - ―
52-Week Range€2.32 - €3.80
Previous CloseN/A
Volume0.00
Average Volume (3M)39.00
Market Cap
€28.64M
Enterprise Value€32.94M
Total Cash (Recent Filing)€3.16M
Total Debt (Recent Filing)€8.96M
Price to Earnings (P/E)―
Beta-0.18
Next Earnings
Oct 09, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding8,062,650
10 Day Avg. Volume0
30 Day Avg. Volume39
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.73
Price to Sales (P/S)1.02
P/FCF Ratio6.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.1
Revenue Forecast (FY)€26.32M
Bulls Say, Bears Say
Bulls Say
Positive Free Cash FlowPositive operating and free cash flow provide internal funding for operations despite reported net losses. This cash conversion can support ongoing laboratory and storage activities, reduce reliance on external financing, and provide some resilience over the next several quarters if cash generation persists.
Strong Gross MarginA gross margin near 77% indicates that the core service offering retains substantial economics after direct costs. If maintained, this gives management a meaningful base from which to address overhead, improve operating leverage, and potentially restore profitability as revenue stabilizes.
Recurring Storage Revenue ModelThe combination of upfront processing revenue and recurring storage fees can create a durable revenue base from each enrolled family. Client retention and long-term preservation services may support revenue visibility and improve customer economics beyond the initial collection event.
Bears Say
Sharp Revenue DeclineA sharp top-line contraction weakens the scale benefits of the business and makes fixed overhead harder to absorb. Continued revenue pressure could reduce new enrollments and future storage additions, limiting the company’s ability to sustain cash generation and improve earnings.
Persistent UnprofitabilityNegative operating profit and net income show that the strong gross margin is currently insufficient to cover the company’s broader cost base. Repeated swings between profits and losses reduce earnings visibility and make durable improvement dependent on renewed revenue growth or cost discipline.
Deeply Negative EquityDeeply negative equity indicates a strained capital structure and limits financial flexibility even though reported debt is low. This weak balance-sheet position can constrain investment capacity, reduce tolerance for operating setbacks, and make the company more dependent on continued cash generation.
Cryo-Cell International News
ZCY FAQ
What was Cryo-Cell International Inc’s price range in the past 12 months?
Cryo-Cell International Inc lowest stock price was €2.32 and its highest was €3.80 in the past 12 months.
What is Cryo-Cell International Inc’s market cap?
Cryo-Cell International Inc’s market cap is €28.64M.
When is Cryo-Cell International Inc’s upcoming earnings report date?
Cryo-Cell International Inc’s upcoming earnings report date is Oct 09, 2026 which is in 3 days.
How were Cryo-Cell International Inc’s earnings last quarter?
Cryo-Cell International Inc released its earnings results on Jul 15, 2026. The company reported €0.062 earnings per share for the quarter, beating the consensus estimate of €0 by €0.062.
Is Cryo-Cell International Inc overvalued?
According to Wall Street analysts Cryo-Cell International Inc’s price is currently Overvalued.
Does Cryo-Cell International Inc pay dividends?
Cryo-Cell International Inc does not currently pay dividends.
What is Cryo-Cell International Inc’s EPS estimate?
Cryo-Cell International Inc’s EPS estimate is 0.03.
How many shares outstanding does Cryo-Cell International Inc have?
Cryo-Cell International Inc has 8,062,650 shares outstanding.
What happened to Cryo-Cell International Inc’s price movement after its last earnings report?
Cryo-Cell International Inc reported an EPS of €0.062 in its last earnings report, beating expectations of €0. Following the earnings report the stock price went up 4.348%.
Which hedge fund is a major shareholder of Cryo-Cell International Inc?
Currently, no hedge funds are holding shares in DE:ZCY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cryo-Cell International Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.92%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-5.79%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cryo-Cell International Inc
Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells. In addition, the company provides cold storage services to third-party pharmaceutical companies and medical institutions. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Technical Analysis
Concord Medical Services
―
Strata Critical Medical
―
NewGenIvf Group
―
Basel Medical Group Ltd
―
20/20 Biolabs, Inc.
―